NASDAQ:MCRB - Seres Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $8.12 -0.15 (-1.81 %) (As of 07/23/2018 04:04 AM ET)Previous Close$8.12Today's Range$8.08 - $8.3552-Week Range$6.65 - $17.42Volume49,233 shsAverage Volume141,133 shsMarket Capitalization$330.10 millionP/E Ratio-3.67Dividend YieldN/ABeta0.51 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company is also developing SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. In addition, its product candidates in pre-clinical development comprise SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; SER-401 for use with checkpoint inhibitors in patients with solid tumors; and SER-155, an Ecobiotic microbiome therapeutic candidate for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Receive MCRB News and Ratings via Email Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:MCRB CUSIPN/A Webwww.serestherapeutics.com Phone617-945-9626 Debt Debt-to-Equity Ratio0.85 Current Ratio3.60 Quick Ratio3.60 Price-To-Earnings Trailing P/E Ratio-3.67 Forward P/E Ratio-3.21 P/E GrowthN/A Sales & Book Value Annual Sales$32.10 million Price / Sales10.28 Cash FlowN/A Price / CashN/A Book Value$1.50 per share Price / Book5.41 Profitability EPS (Most Recent Fiscal Year)($2.21) Net Income$-89,380,000.00 Net Margins-277.79% Return on Equity-150.44% Return on Assets-47.26% Miscellaneous Employees138 Outstanding Shares40,650,000Market Cap$330.10 Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions What is Seres Therapeutics' stock symbol? Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB." How were Seres Therapeutics' earnings last quarter? Seres Therapeutics Inc (NASDAQ:MCRB) issued its quarterly earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.06. The biotechnology company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $3 million. Seres Therapeutics had a negative return on equity of 150.44% and a negative net margin of 277.79%. View Seres Therapeutics' Earnings History. When is Seres Therapeutics' next earnings date? Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Seres Therapeutics. What price target have analysts set for MCRB? 8 Wall Street analysts have issued 12-month target prices for Seres Therapeutics' stock. Their predictions range from $19.00 to $20.00. On average, they anticipate Seres Therapeutics' stock price to reach $19.3333 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price. View Analyst Ratings for Seres Therapeutics. What is the consensus analysts' recommendation for Seres Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Seres Therapeutics' key competitors? Some companies that are related to Seres Therapeutics include Myovant Sciences (MYOV), Radius Health (RDUS), Uniqure (QURE), Eagle Pharmaceuticals (EGRX), Alder Biopharmaceuticals (ALDR), Zai Lab (ZLAB), Reata Pharmaceuticals (RETA), Retrophin (RTRX), Endocyte (ECYT), Athenex (ATNX), Tricida (TCDA), Esperion Therapeutics (ESPR), Wave Life Sciences (WVE), Intra-Cellular Therapies (ITCI) and Vanda Pharmaceuticals (VNDA). Who are Seres Therapeutics' key executives? Seres Therapeutics' management team includes the folowing people: Dr. Roger James Pomerantz, Chairman, Pres & CEO (Age 61)Mr. Eric D. Shaff, Exec. VP, Chief Operating & Financial Officer and Treasurer (Age 42)Dr. Michele Trucksis, Exec. VP & Chief Medical Officer (Age 65)Dr. John G. Aunins, CTO and Exec. VP of Bioprocess & Manufacturing (Age 57)Dr. David N. Cook, Exec. VP of R&D and Chief Scientific Officer (Age 60) When did Seres Therapeutics IPO? (MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. Has Seres Therapeutics been receiving favorable news coverage? Press coverage about MCRB stock has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Seres Therapeutics earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 46.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. How do I buy shares of Seres Therapeutics? Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Seres Therapeutics' stock price today? One share of MCRB stock can currently be purchased for approximately $8.12. How big of a company is Seres Therapeutics? Seres Therapeutics has a market capitalization of $330.10 million and generates $32.10 million in revenue each year. The biotechnology company earns $-89,380,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis. Seres Therapeutics employs 138 workers across the globe. How can I contact Seres Therapeutics? Seres Therapeutics' mailing address is 200 SIDNEY STREET 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626. MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 231 (Vote Outperform)Underperform Votes: 183 (Vote Underperform)Total Votes: 414MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe MCRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MCRB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?